Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;24(6):2793-805.
doi: 10.1007/s00520-016-3153-y. Epub 2016 Mar 17.

Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols

Judith A E M Zecha  1 , Judith E Raber-Durlacher  1   2 , Raj G Nair  3 , Joel B Epstein  4   5 , Sharon Elad  6 , Michael R Hamblin  7   8   9 , Andrei Barasch  10 , Cesar A Migliorati  11 , Dan M J Milstein  1 , Marie-Thérèse Genot  12 , Liset Lansaat  13 , Ron van der Brink  5 , Josep Arnabat-Dominguez  14 , Lisette van der Molen  13 , Irene Jacobi  13 , Judi van Diessen  15 , Jan de Lange  1 , Ludi E Smeele  1   13 , Mark M Schubert  16 , René-Jean Bensadoun  17
Affiliations
Review

Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols

Judith A E M Zecha et al. Support Care Cancer. 2016 Jun.

Abstract

Purpose: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed.

Methods: Narrative review and presentation of PBM parameters are based on current evidence and expert opinion.

Results: PBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780-830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2-3 J (J/cm(2)), and no more than 6 J/cm(2) on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (<100 Hz); and route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations.

Conclusion: PBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.

Keywords: Chemotherapy; Head and neck cancer; LLLT; Low-level laser therapy; Low-level light therapy; Mucositis; Orofacial complications; PBM; Photobiomodulation; Radiation therapy.

PubMed Disclaimer

References

    1. Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–422. doi: 10.3322/caac.21157. - DOI - PubMed
    1. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–2713. doi: 10.1002/cncr.23898. - DOI - PubMed
    1. Cooperstein E, Gilbert J, Epstein JB, Dietrich MS, Bond SM, Ridner SH, et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck. 2012;34(6):797–804. doi: 10.1002/hed.21816. - DOI - PubMed
    1. Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013;85(4):935–940. doi: 10.1016/j.ijrobp.2012.08.030. - DOI - PMC - PubMed
    1. Verdonck-de Leeuw IM, Buffart LM, Heymans MW, Rietveld DH, Doornaert P, de Bree R, et al. The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study. Radiother Oncol: J Eur Soc Ther Radiol Oncol. 2014;110(3):422–428. doi: 10.1016/j.radonc.2014.01.002. - DOI - PubMed

MeSH terms